Systemic Bio, a subsidiary of 3D Systems, has been honored with the SLAS 2025 Innovation Award. The award honors technological developments that have the potential to significantly change scientific research and automation in laboratories. The award was presented at the SLAS International Conference and Exhibition, which showcases innovative solutions in the life sciences every year.
The company received the award for its h-VIOS platform, which provides bio-printed human tissues for drug research. The technology is used to assess the safety of antibody drug conjugates (ADCs) at an early stage. The aim is to identify risks that until now have often only become apparent in clinical trials. In the past, even tests on non-human primates could not always predict all potential side effects. The use of h-VIOS technology could improve this process and thus reduce the risk of later setbacks in drug development.
“I couldn’t be prouder of our team for winning this award,” said Taci Pereira, CEO of Systemic Bio. “This recognition is a testament to our relentless focus on demonstrating the scientific and translational value of our platform. We remain committed to expanding our capabilities and accelerating adoption to improve drug discovery and development.”
Systemic Bio’s manufacturing facility in Houston, Texas, has ISO 7 class clean room capabilities and a quality management system (QMS). Thousands of tissue models can be produced there, which are used for pharmaceutical research collaborations. The aim is to improve preclinical tests and reduce the likelihood of subsequent failures.
The SLAS Innovation Award is given to technologies that make a relevant contribution to laboratory automation. The recognition underlines the importance of bioprinting for drug research and could lead to the faster introduction of new methods in the pharmaceutical industry.
Subscribe to our Newsletter
3DPresso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.
